Rani Therapeutics Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
RANI$0.57+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except par value)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $18,618 | $3,762 |
| Accounts receivable | 2,042 | — |
| Contract asset | — | 428 |
| Marketable securities | 31,091 | 23,877 |
| Prepaid expenses and other current assets | 1,570 | 1,677 |
| Total current assets | 53,321 | 29,744 |
| Property and equipment, net | 736 | 1,548 |
| Operating lease right-of-use asset | 4,318 | 5,096 |
| Other assets | 246 | 246 |
| Total assets | $58,621 | $36,634 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $309 | $1,359 |
| Accrued expenses and other current liabilities | 3,943 | 2,073 |
| Current portion of deferred revenue | 6,831 | — |
| Current portion of long-term debt | — | 15,000 |
| Current portion of operating lease liability | 1,586 | 1,459 |
| Total current liabilities | 12,669 | 19,891 |
| Long-term deferred revenue | 1,708 | — |
| Long-term debt, less current portion | — | 9,613 |
| Operating lease liability, less current portion | 2,732 | 3,637 |
| Total liabilities | 17,109 | 33,141 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Class A common stock, $0.0001 par value - 800,000 shares authorized; 97,622 and 33,430 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 9 | 3 |
| Class B common stock, $0.0001 par value - 40,000 shares authorized; 23,970 and 23,972 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 2 | 2 |
| Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of December 31, 2025 and December 31, 2024 | — | — |
| Additional paid-in capital | 165,578 | 104,889 |
| Accumulated other comprehensive gain | 1 | 5 |
| Accumulated deficit | (132,580) | (102,907) |
| Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. | 33,010 | 1,992 |
| Non-controlling interest | 8,502 | 1,501 |
| Total stockholders' equity | 41,512 | 3,493 |
| Total liabilities and stockholders' equity | $58,621 | $36,634 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.